Chronic hepatitis B (CHB) infection remains a significant global public health concern. Functional cure, defined as hepatitis B surface antigen seroclearance with unquantifiable HBV DNA at 24 weeks off treatment, is a desirable endpoint in the treatment of CHB, yet challenging to achieve. Given the limitations of current therapies including nucleos(t)ide analogues and pegylated interferon alpha, novel agents targeting functional cure are emerging. As hepatitis B virus (HBV) is a non-cytolytic virus, liver damage stems from the host immune response towards HBV-infected cells. The innate immune response during the initial phase of HBV infection is crucial in establishing an adequate level of immunity against the virus. However, HBV adopts various mechanisms to evade the host’s innate immunity, partly contributing to the chronicity of infection. This article provides a comprehensive review on how the HBV life cycle interacts with the host’s innate immune system. The latest evidence of novel agents targeting the innate immunity will also be covered. Retinoic acid inducible gene I agonists, toll-like receptor agonists, and interferons are therapies that target the HBV evasion strategies against host’s innate immunity. While small interfering RNAs and antisense oligonucleotides are originally designed for antigen knockdown and reinvigoration of the adaptive immune response, they have also shown additional impacts on the innate immunity. With ongoing research and innovation in combination strategies, advancement in the management of CHB is anticipated in the future.
HCC predictors in routine practice for patients with chronic liver diseases: Correspondence to editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease” Tung-Hung Su, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e52. CrossRef
Backgrounds/Aims Plasma pregenomic hepatitis B virus RNA (pgRNA) is a novel biomarker in chronic hepatitis B infection (CHB). We aimed to describe the longitudinal profile of pgRNA and factors influencing its levels in CHB patients on nucleoside analogue (NUC).
Methods Serial plasma samples from 1,354 CHB patients started on first-line NUC were evaluated. Time of NUC initiation was taken as baseline (year 0), followed by 1-year, 3-year and 5-year of NUC therapy. pgRNA was measured by Research Use Only RealTime HBV RNA v2.0 (0.2 mL) (Abbott Diagnostics) with lower limit of detection of 0.8 log U/mL (~20 copies/mL).
Results Among 1,354 subjects (median age at baseline 49.8 [interquartile range, IQR 40.2–57.3]) years, 65.2% male, 16.1% hepatitis B e antigen (HBeAg)-positive, 28.6% cirrhotic), baseline median HBV RNA was 3.68 (IQR 2.42–5.19) log U/mL. Upon NUC therapy, median pgRNA levels were 2.45 (IQR 1.82–3.62), 2.23 (IQR 1.67–3.05) and 2.14 (IQR 1.48–2.86) log U/mL at 1, 3 and 5 years, respectively, with the corresponding log U/mL reductions of 0.82, 1.20 and 1.54. Undetectable/ unquantifiable pgRNA was achieved in 13.5%, 15.9% and 20.1% of patients at 1, 3 and 5 years, respectively. Older age, male sex, HBeAg-negativity and high PAGE-B score were associated with lower pgRNA.
Conclusions Plasma pgRNA declines are modest under NUC therapy, with only 16.3% achieving RNA undetectability after 5 years of first-line NUC indicating cccDNA silencing has not been achieved in the majority of patients. Clinical characteristics should be taken into consideration when interpreting the plasma pgRNA level.
Citations
Citations to this article as recorded by
Robust mission-driven responses to infectious disease threats delivered by the Abbott pandemic defense coalition Mary A. Rodgers, Francisco Averhoff, Michael G. Berg, Mark Anderson, Carolyn Strobel, Julissa Inostroza, James Moy, Jorge Mera, Paul J. Utz, Scott C. Weaver, Charles Y. Chiu, Judith C. De Arcos, Joshua J. Anzinger, Jean H. Henrys, Juan P. Hernandez-Ortiz, International Journal of Infectious Diseases.2026; 162: 108162. CrossRef
Profiles and kinetics of PgRNA and clinical characteristics in pregnant, postpartum, and non-pregnant women with chronic HBV infection Genju Wang, Yandan Wu, Ziyue Zhang, Qiuchen Wu, Juan Tang, Ying Ji, Yan Wang, Guanlun Zhou, Minmin Yu Virology Journal.2025;[Epub] CrossRef
Chronic hepatitis B (CHB) poses a major global public health challenge and is a leading cause of cirrhosis and liver cancer. Hepatic steatosis is common in individuals with CHB compared to the non-CHB population and is particularly prevalent in hepatitis B virus (HBV)-endemic regions, affecting about one-third of CHB patients. The interaction between hepatic steatosis and CHB-related disease progression is complex and still under debate. Evidence demonstrates that co-existing steatosis may worsen liver fibrosis while paradoxically increasing the likelihood of achieving better HBV control. In particular, despite the association of steatotic liver disease (SLD) with lower HBV viral loads and higher rates of HBsAg seroclearance, the coexistence of CHB and SLD can potentially accelerate liver disease progression. Factors such as fat deposition, lipotoxicity, oxidative stress, and chronic inflammation in SLD may foster a pro-fibrotic and pro-carcinogenic environment, accelerating the disease progression. Additionally, loss of global DNA methylation, changes in the immune microenvironment, and genetic susceptibility further contribute to the development of CHB-related cirrhosis and hepatocellular carcinoma (HCC). This review examines the mechanisms driving liver disease progression and the heightened risk of cirrhosis and HCC in patients with concurrent CHB and steatotic liver disease, underscoring the importance of prioritizing antiviral therapy for CHB in addition to addressing SLD.
Citations
Citations to this article as recorded by
Letter to the editor on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Sisi Yang, Zhenxuan Ma Clinical and Molecular Hepatology.2026; 32(1): e4. CrossRef
Evaluation of PNPLA3 genetic variants in Egyptian HBV-infected patients concomitant with metabolic-associated steatotic liver disease (MASLD) Mai Abd El-Meguid, Ghada M. Salum, Basma E. Fotouh, Naglaa Zayed, Shereen Abdel Alem, Ayman Yosry, Reham M. Dawood Diagnostic Microbiology and Infectious Disease.2026; 114(2): 117105. CrossRef
Diagnostic Performance of Ultrasound-Derived Fat Fraction and Automated Point Shear Wave Elastography for Hepatic Steatosis and Fibrosis in Suspected Steatotic Liver Disease: A Prospective Multicenter Study Jing Liang, Xueqi Li, Guangwen Cheng, Huixiong Xu, Yuli Zhu, Zhe Ma, Dong Jiang, Hao Han, Lin Chen, Liyun Xue, Xiaohui Qiao, Hong Ding Ultrasound in Medicine & Biology.2026; 52(1): 227. CrossRef
Pollutants in Microenvironmental Cellular Interactions During Liver Inflammation Cancer Transition and the Application of Multi-Omics Analysis Yulun Jian, Yuhan Li, Yanfeng Zhou, Wei Mu Toxics.2025; 13(3): 163. CrossRef
Identification and evaluation of biomarkers for diagnosis of chronic hepatitis B using RNA-seq Hong Hong, Xintong Han, Qiuxiang Hu, Huafeng Song, Bing Han Virus Research.2025; 358: 199589. CrossRef
Unraveling the metabolic thread: Type 2 diabetes and fibrosis in chronic hepatitis B with steatosis Won-Mook Choi, Wai-Kay Seto Hepatology.2025;[Epub] CrossRef
Exosome in HBV infection: current concepts and future perspectives XueLan Yuan, ChunXia Huang, Yan Ran Frontiers in Cellular and Infection Microbiology.2025;[Epub] CrossRef
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs Angela Chau, Jie Li, Dae Won Jun, Yao‐Chun Hsu, Hidenori Toyoda, Ming‐Lun Yeh, Tsunamasa Watanabe, Takashi Honda, Huy Trinh, Akito Nozaki, Haruki Uojima, Toru Ishikawa, Daniel Q. Huang, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masanori Atsukawa, Ma Journal of Viral Hepatitis.2025;[Epub] CrossRef
Preoperative HBsAg seroclearance affects long-term outcomes for hepatitis B virus-related hepatocellular carcinoma after liver resection: a multicenter analysis Si-Yu Liu, Lin Zhu, Wen-Feng Lu, Gui-Lin Xie, Lei Liang, Jun-Wei Liu, Bin Ye, Mu-Gen Dai BMC Cancer.2025;[Epub] CrossRef
Efficacy and safety of bifidobacterium triple viable capsules combined with entecavir in the treatment of Hepatitis B cirrhosis Rongquan Liu, Yun Ji, Jie Zhang Biomedical Papers.2025;[Epub] CrossRef
EMP1 + hepatic stellate cells drive hepatic fibrosis progression to hepatocellular carcinoma and predict prognosis Jie You, Yihuan Huang, Chenhao Jiang, Jiaqi Xiao, Jiebin Zhang, Yasong Liu, Xin Sui, Yingcai Zhang, Jia Yao, Tongyu Lu Journal of Translational Medicine.2025;[Epub] CrossRef
Prognostic Value of the PET/CT-Derived Maximum Standardized Uptake Value Combined with the Neutrophil–Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy Tianyi Zhou, Chaoliu Dai Current Oncology.2025; 33(1): 13. CrossRef
Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic hepatitis B (CHB). Nonetheless, functional cure is rarely attained with the current treatment modalities of nucleos(t)ide analogues (NUCs) and pegylated interferon alpha. Multiple novel virus-targeting agents and immunomodulators are under development for HBV with functional cure as the treatment goal. Among virus-targeting agents, antisense oligonucleotides and small-interfering RNAs are the most advanced in the developmental pipeline, and can induce potent and sustainable HBsAg suppression. The other virus-targeting agents have varying effects on HBsAg and HBV DNA, depending on the drug mechanism. In contrast, immunomodulators have modest effects on HBsAg and have limited roles in monotherapy. Multiple combination regimens incorporating RNA interference agents with immunomodulators have been studied through many ongoing clinical trials. These combination strategies demonstrate synergistic effects in inducing functional cure, and will likely be the future direction of development. Despite the promising results, research is warranted to optimize treatment protocols and to establish criteria for NUC withdrawal after novel therapies. Functional cure is now an attainable target in CHB, and the emerging novel therapeutics will revolutionize CHB management.
Citations
Citations to this article as recorded by
Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen Gut.2026; 75(1): 119. CrossRef
Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial” Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “Glutamate dehydrogenase 1-dependent α-ketoglutarate promotes hepatitis B virus transcription by modulating histone methylations on the covalentl Mehrangiz Dezhbord, Kyun-Hwan Kim Clinical and Molecular Hepatology.2026; 32(1): 385. CrossRef
Targeting the innate immune system in treating hepatitis B: prospects for functional cure Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Clinical and Molecular Hepatology.2026; 32(1): 184. CrossRef
Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients Yandan Wu, Yu Zhao, Ruixue Ji, Pinqing Li, Huijuan Chen, Fangping Yue, Yi Wu, Jie Qiu, Chuanlai Shen Frontiers in Immunology.2026;[Epub] CrossRef
Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy” Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen Journal of Hepatology.2025; 82(5): e228. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients? Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Hepatology International.2025; 19(2): 304. CrossRef
Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider? Shang-Chin Huang, Jia-Horng Kao Expert Review of Gastroenterology & Hepatology.2025; 19(4): 371. CrossRef
Efficacy of Antiviral Therapy in Chronic Hepatitis B Patients With Normal Alanine Aminotransferase: A Systematic Review and Meta‐Analysis Yuting Diao, Yueying Zeng, Zhihao Huang, Chunfang You, Kevork M. Peltekian Canadian Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef
Hepatitis B: Neue therapeutische Ansätze für eine funktionelle Heilung Markus Cornberg, Ulrike Protzer Deutsches Ärzteblatt Online.2025;[Epub] CrossRef
Structural optimization of phthalazine derivatives for anti-HBV activities to improve oral bioavailability Yurong Yang, Fuling Xiao, Jianping Zuo, Li Yang, Youhong Hu, Wuhong Chen Bioorganic & Medicinal Chemistry.2025; 128: 118259. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Hepatology International.2025; 19(4): 704. CrossRef
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure Ana Verma, Raymond T. Chung Current Opinion in HIV and AIDS.2025; 20(5): 449. CrossRef
Challenges and advances in clinical cure of chronic hepatitis B Xu-Ling Liu, Yu-Lang Jiang, Ming-Yu Sun World Chinese Journal of Digestology.2025; 33(9): 693. CrossRef
Small molecule HBV RNA destabilizing drugs: Drugs of the future or compounds from the past? Timothy M. Block, Dimitar Gotchev, Yanming Du Antiviral Research.2025; 244: 106288. CrossRef
Global strategies and actions to eliminate hepatitis B virus infection Chih-Lin Lin, Jia-Horng Kao Clinical and Molecular Hepatology.2025; 31(4): 1197. CrossRef
Morphometric and structural dynamic parameters of hepatitis viruses: implications for therapeutic and vaccine failure Saganuwan Alhaji Saganuwan Discover Viruses.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao Hepatoma Research.2025;[Epub] CrossRef
Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after vira Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu Clinical and Molecular Hepatology.2025; 31(1): e64. CrossRef
Reply to comment on “Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program” Hung-Wei Wang, Cheng-Yuan Peng, Ming-Lung Yu Journal of the Formosan Medical Association.2025;[Epub] CrossRef
From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease Andrea Pasta, Elena Formisano, Francesco Calabrese, Elisa Marabotto, Manuele Furnari, Giorgia Bodini, Maria Corina Plaz Torres, Livia Pisciotta, Edoardo Giovanni Giannini, Patrizia Zentilin Microorganisms.2025; 13(2): 241. CrossRef
Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto Clinical and Molecular Hepatology.2025; 31(Suppl): S182. CrossRef
In response to: Steatotic liver disease-know your enemies Michael H. Le, Linda Henry, Mindie H. Nguyen Clinical and Molecular Hepatology.2024; 30(2): 284. CrossRef
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma Lung-Yi Mak Journal of Liver Cancer.2024; 24(2): 145. CrossRef
Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess viral activity. In this review article, we summarize the relevant data of how antiviral therapies impact viral biomarkers, and discuss their potential implications. Viral nucleic acids including hepatitis B virus (HBV) double-stranded deoxy-ribonucleic acid (DNA) and to a lesser extent, pre-genomic RNA, are readily suppressed by nucleos(t)ide analogues (NUCs). The primary role of these markers include risk prediction for hepatocellular carcinoma (HCC) and risk stratification for partial cure, defined as off-therapy virological control, or functional cure, defined as hepatitis B surface antigen (HBsAg) seroclearance plus undetectable serum HBV DNA for ≥6 months. Viral translational products including hepatitis e antigen, quantitative HBsAg and hepatitis B core-related antigen can be reduced by NUCs and pegylated interferon a. They are important in defining disease phase, delineating treatment endpoints, and predicting clinical outcomes including HCC risk and partial/ functional cure. As the primary outcome of phase III trials in chronic hepatitis B is set as HBsAg seroclearance, appropriate viral biomarkers can potentially inform the efficacy of novel compounds. Early viral biomarker response can help with prioritization of subjects into clinical trials. However, standardization and validation studies would be crucial before viral biomarkers can be broadly implemented in clinical use.
Citations
Citations to this article as recorded by
Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen Gut.2026; 75(1): 119. CrossRef
Investigational RNA Interference Agents for Hepatitis B Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen BioDrugs.2025; 39(1): 21. CrossRef
Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure Yue Qiu, Qiao Tang, Xiao-Qing Liu, Yun-Ling Xue, Yi Zeng, Peng Hu World Journal of Hepatology.2025;[Epub] CrossRef
Prospect of emerging treatments for hepatitis B virus functional cure Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2025; 31(Suppl): S165. CrossRef
Development and Validation of a High‐Sensitivity Droplet Digital PCR Assay for Serum Hepatitis B Virus DNA Detection Rex Wan‐Hin Hui, Danny Ka‐Ho Wong, Lung‐Yi Mak, James Fung, Wai‐Kay Seto, Man‐Fung Yuen Journal of Viral Hepatitis.2025;[Epub] CrossRef
Functional Cure for Hepatitis B Virus: Challenges and Achievements Oren Shechter, Daniel G. Sausen, Harel Dahari, Andrew Vaillant, Scott J. Cotler, Ronen Borenstein International Journal of Molecular Sciences.2025; 26(8): 3633. CrossRef
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen Clinical and Molecular Hepatology.2025; 31(2): 460. CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Hepatology International.2025; 19(4): 704. CrossRef
Simplified flow cytometry-based assay for rapid multi-cytokine profiling and machine-learning-assisted diagnosis of inflammatory diseases Qiang Quan, Xuegui Ju, Guangmei Li, Lu Ye, Sichong Ren, Shuxin Yang, Rui Zhang, Hui Wang, Ruyue Lin, Luoting Yu Frontiers in Pharmacology.2025;[Epub] CrossRef
Prise en charge du porteur de l’antigène HBs F.H. Pujol, R. Jaspe, C. Trépo, I. Chemin EMC - Hépatologie.2025; 40(4): 1. CrossRef
Challenges and advances in clinical cure of chronic hepatitis B Xu-Ling Liu, Yu-Lang Jiang, Ming-Yu Sun World Chinese Journal of Digestology.2025; 33(9): 693. CrossRef
Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies Ivana Lazarevic, Ana Banko, Danijela Miljanovic, Maja Cupic Pathogens.2024; 13(1): 46. CrossRef
ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B Ryan Hin-Man Leung, Rex Wan-Hin Hui, Lung-Yi Mak, Xianhua Mao, Kevin Sze-Hang Liu, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Man-Fung Yuen Journal of Hepatology.2024; 81(2): 218. CrossRef
Lack of association between early on-treatment HBeAg seroclearance and development of hepatocellular carcinoma or decompensated cirrhosis Hyunjae Shin, Won-Mook Choi, Seung Up Kim, Yunmi Ko, Youngsu Park, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Fabien Zoulim JHEP Reports.2024; 6(7): 101089. CrossRef
Linvencovir: Paving the way for functional cure in hepatitis B Jiwon Yang, Jonggi Choi Clinical and Molecular Hepatology.2024; 30(2): 164. CrossRef
Editorial: High qHBsAg—is it a good or bad signal? Beom Kyung Kim Alimentary Pharmacology & Therapeutics.2024; 59(12): 1616. CrossRef
Role of hepatitis B core‐related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta‐analysis Qi‐Hang Cao, Hui Liu, Lun‐Jie Yan, Han‐Chao Wang, Zi‐Niu Ding, Xin‐Cheng Mao, Rui‐Zhe Li, Guo‐Qiang Pan, Xiao Zhang, Bao‐Wen Tian, Cheng‐Long Han, Zhao‐Ru Dong, Si‐Yu Tan, Dong‐Xu Wang, Yu‐Chuan Yan, Tao Li Journal of Gastroenterology and Hepatology.2024; 39(8): 1464. CrossRef
Current perspectives of viral hepatitis Daisuke Usuda, Yuki Kaneoka, Rikuo Ono, Masashi Kato, Yuto Sugawara, Runa Shimizu, Tomotari Inami, Eri Nakajima, Shiho Tsuge, Riki Sakurai, Kenji Kawai, Shun Matsubara, Risa Tanaka, Makoto Suzuki, Shintaro Shimozawa, Yuta Hotchi, Ippei Osugi, Risa Katou, World Journal of Gastroenterology.2024; 30(18): 2402. CrossRef
Extended analysis on peripheral blood cytokines correlated with hepatitis B virus viral load in chronically infected patients – a systematic review and meta-analysis Marina Manea, Ion Mărunțelu, Ileana Constantinescu Frontiers in Medicine.2024;[Epub] CrossRef
Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction” Cho-Rong Lee, Sung-Gyoo Park Clinical and Molecular Hepatology.2024; 30(4): 724. CrossRef
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B pati Beom Kyung Kim Clinical and Molecular Hepatology.2024; 30(4): 656. CrossRef
CD4+ T cell counts and soluble programmed death-1 at baseline correlated with hepatitis B surface antigen decline in HIV/HBV coinfection during combined antiretroviral therapy Xiaodi Li, Ling Xu, Lianfeng Lu, Xiaosheng Liu, Yang Yang, Yuanni Wu, Yang Han, Xiaoxia Li, Yanling Li, Xiaojing Song, Wei Cao, Taisheng Li Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Opportunities and challenges for hepatitis B cure Armando Andres Roca Suarez, Fabien Zoulim eGastroenterology.2023; 1(2): e100021. CrossRef
Non-Invasive Prediction Scores for Hepatitis B Virus- and Hepatitis D Virus-Infected Patients—A Cohort from the North-Eastern Part of Romania Laura Iulia Grecu, Camelia Sultana, Mariana Pavel-Tanasa, Simona Maria Ruta, Mihaela Chivu-Economescu, Lilia Matei, Ramona Gabriela Ursu, Elena Iftimi, Luminita Smaranda Iancu Microorganisms.2023; 11(12): 2895. CrossRef
Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load, extensive local expertise on HCC has been accumulated. This article summarized local guidelines and real-life practice on HCC management in Hong Kong. For HCC surveillance, liver ultrasound and serum alpha-fetoprotein for periodic screening is recommended in viral hepatitis or cirrhotic patients, and this is adhered to in clinical practice. HCC diagnosis is not covered in local guidelines, yet our practice is in-line with regional guidelines, where diagnosis is usually achieved by cross-sectional imaging and without the need for histology. Our guidelines recommend using the Hong Kong Liver Cancer Staging for pre-treatment staging, yet we routinely use other widely-adopted systems such as the Barcelona Clinic Liver Cancer Staging and the Tumor-Node-Metastasis Staging as well. Our local guidelines have provided clear treatment algorithms for the whole range of HCC therapies, including resection, ablation, transplant, transarterial chemoembolization, transarterial radioembolization, stereotactic body radiation therapy, targeted therapy, and immunotherapy. Real-life treatment choices are largely in line with the guidelines, although treatment protocols are individualized, and availability of specific therapies can vary between centers. Overall, HCC guidelines in Hong Kong are tailored based on local expertise and our unique patient population. The guidelines are up-to-date and provide practical pathways to assist our routine practice. Regular updates of local guidelines are warranted to account for the rapidly evolving paradigm of HCC management.
Citations
Citations to this article as recorded by
Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen Gut.2026; 75(1): 119. CrossRef
A systematic review of MicroRNA (miRNA) biomarkers in the diagnosis and prognosis of hepatocellular carcinoma J. M. John Britto, T Beula Bell Irish Journal of Medical Science (1971 -).2026;[Epub] CrossRef
Advancements in locoregional therapy for advanced hepatocellular carcinoma: Emerging perspectives on combined treatment strategies Qi Liu, Renjie Zhang, Weixi Shen European Journal of Surgical Oncology.2025; 51(2): 109502. CrossRef
Investigational RNA Interference Agents for Hepatitis B Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen BioDrugs.2025; 39(1): 21. CrossRef
Gold(I) complexes bearing EGFR-inhibiting ligands as anti-HCC agents through dual targeting of EGFR and TrxR Yawen Wang, Xiaoyan Ma, Xuejie Chen, Zhenfan Wen, Chunyang Bi, Zhongren Xu, Wukun Liu European Journal of Medicinal Chemistry.2025; 283: 117137. CrossRef
Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery Rex Wan-Hin Hui, Keith Wan-Hang Chiu, I-Cheng Lee, Chenlu Wang, Ho-Ming Cheng, Jianliang Lu, Xianhua Mao, Sarah Yu, Lok-Ka Lam, Lung-Yi Mak, Tan-To Cheung, Nam-Hung Chia, Chin-Cheung Cheung, Wai-Kuen Kan, Tiffany Cho-Lam Wong, Albert Chi-Yan Chan, Yi-Hsia Hepatology.2025; 82(2): 344. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients? Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Hepatology International.2025; 19(2): 304. CrossRef
Prospect of emerging treatments for hepatitis B virus functional cure Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2025; 31(Suppl): S165. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Hepatology International.2025; 19(4): 704. CrossRef
Comparative prognostic performance of staging systems for hepatocellular carcinoma: Evidence from a Vietnamese cohort study Tuong-Anh Mai-Phan, Trong-Kha Nguyen, Tri-Nhan Pham, Minh-Quang Tran, Kim-Long Le World Journal of Hepatology.2025;[Epub] CrossRef
The Prevailing Role of Diabetes Mellitus Among Cardiometabolic Risk Factors in Metabolic Dysfunction-associated Steatotic Liver Disease Prognostication Karen Cheuk-Ying Ho, Lung-Yi Mak Journal of Clinical and Experimental Hepatology.2025; 15(5): 103119. CrossRef
15-Year Trends in Hepatocellular Carcinoma: Epidemiology, Treatment, and Outcomes from a Hospital-Based Registry Songgyung Kim, Jina Park, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Ki-Hun Kim, Jonggi Choi Gut and Liver.2025; 19(5): 746. CrossRef
Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors Rex Wan-Hin Hui, Matthew Shing-Hin Chung, Lu Li, Xianhua Mao, Chi-Leung Chiang, Carlos King-Ho Wong, Ian Chi-Kei Wong, Ka-Shing Cheung, Man-Fung Yuen, Wai-Kay Seto, Lung-Yi Mak JHEP Reports.2025; 7(11): 101578. CrossRef
Development of a novel routine blood-based AI model for hepatocellular carcinoma screening—a territory-wide study K.-N. Kwok, K.-M. Chueng, S.J.-L. Lam, M. Seo, C.Y. Lau, P.Y.-M. Woo, H.-S. Lam, S.-M. Yip, S. Lam, O.-P. Chiu, W.W.Y. Sung, H.H.-W. Liu, K.K.-H. Bao, J.C.-H. Chow, S.K.-K. Ng, H.H.-Y. Yiu, D.C.C. Lam ESMO Gastrointestinal Oncology.2025; 10: 100241. CrossRef
Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts Jacqueline Schönherr, Philipp Seifert, Falk Gühne, Thomas Winkens, Falk Rauchfuß, Utz Settmacher, Martin Freesmeyer, Robert Drescher Cancers.2024; 16(1): 235. CrossRef
Hepatocellular carcinoma: Advances in systemic therapies Trevor Kwan-Hung Wu, Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen F1000Research.2024; 13: 104. CrossRef
ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B Ryan Hin-Man Leung, Rex Wan-Hin Hui, Lung-Yi Mak, Xianhua Mao, Kevin Sze-Hang Liu, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Man-Fung Yuen Journal of Hepatology.2024; 81(2): 218. CrossRef
Hepatocellular carcinoma: Advances in systemic therapies Trevor Kwan-Hung Wu, Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen F1000Research.2024; 13: 104. CrossRef
Bioequivalence Study of Velpatasvir/Sofosbuvir Oral Coated Tablets in Healthy Volunteers Under Fasting Conditions Sergei Noskov, Anna Arefeva, Kseniia Radaeva, Igor Makarenko, Maria Gefen, Roman Drai Clinical Pharmacology in Drug Development.2024; 13(10): 1123. CrossRef
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen, James Fung Expert Review of Gastroenterology & Hepatology.2023; 17(5): 443. CrossRef
The prime time for management of hepatocellular carcinoma in Hong Kong Landon L. Chan, Stephen L. Chan Clinical and Molecular Hepatology.2023; 29(2): 345. CrossRef
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(2): 252. CrossRef
World Hepatitis Day 2023: Are we close to the target? Rex Wan-Hin Hui, James Fung Indian Journal of Medical Research.2023; 158(1): 1. CrossRef
Global trends of targeted therapy for hepatocellular carcinoma: A bibliometric and visualized study from 2008 to 2022 Xuan-Ang Yang, Rong Jin, Lei-Ming Zhang, Dong-Jian Ying Medicine.2023; 102(34): e34932. CrossRef
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the 21st century. With the advancement of non-invasive tests for assessing and monitoring of steatosis and fibrosis, NAFLD screening is now feasible, and is increasingly highlighted in international guidelines related to hepatology, endocrinology, and pediatrics. Identifying high-risk populations (e.g., diabetes mellitus, obesity, metabolic syndrome) based on risk factors and metabolic characteristics for non-invasive screening is crucial and may aid in designing screening strategies to be more precise and effective. Many screening modalities are currently available, from serum-based methods to ultrasonography, transient elastography, and magnetic resonance imaging, although the diagnostic performance, cost, and accessibility of different methods may impact the actual implementation. A two-step assessment with serum-based fibrosis-4 index followed by imaging test vibration-controlled transient elastography can be an option to stratify the risk of liverrelated complications in NAFLD. There is a need for fibrosis surveillance, as well as investigating the cost-effectiveness of different screening algorithms and engaging primary care for first-stage triage screening.
Citations
Citations to this article as recorded by
Sustainability of General Population Screening for Steatotic Liver Disease: A Proof-of-Concept Study Laura De Rosa, Gabriele Ricco, Maurizia Rossana Brunetto, Ferruccio Bonino, Francesco Faita Healthcare.2025; 13(7): 759. CrossRef
Bioelectrical impedance analysis parameters are superior to liver enzymes in predicting metabolic dysfunction-associated steatotic liver disease in young adults Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Hye Sun Lee, Young Hoon Youn, Su Jung Baik, Hana Lee, Joon Young Kim, Youngha Choi, Hyun Wook Chae Internal and Emergency Medicine.2025; 20(3): 785. CrossRef
Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study) Viswanathan Mohan, Shashank Joshi, Saket Kant, Altamash Shaikh, L. Sreenivasa Murthy, Banshi Saboo, Parminder Singh, Aravind R. Sosale, Debmalya Sanyal, G. Shanmugasundar, Santosh Kumar Singh, A. K. Pancholia, Sunetra Mondal, Rishi George, Ashok Jaiswal, Diabetes Therapy.2025; 16(7): 1435. CrossRef
Hepatic steatosis index for prediction of metabolic dysfunction‐associated steatotic liver disease (MASLD) among young Indian women with gestational diabetes and normoglycaemia during index pregnancy Alpesh Goyal, Suraj Kubihal, Yashdeep Gupta, Shalimar, Devasenathipathy Kandasamy, Mani Kalaivani, Nikhil Tandon Diabetes, Obesity and Metabolism.2025; 27(10): 6018. CrossRef
Non-invasive detection of fibrosis in non-alcoholic fatty liver disease by serum microfibrillar-associated protein 4 and its correlation with FIB-4 and transient elastography Heba Abdel Rahman Eltony, Gamal Kasem, Radwa Mahmoud Elsharaby, Rehab Badawi, Eman M. Helal Egyptian Liver Journal.2025;[Epub] CrossRef
Evaluation of tri‐ponderal mass index in predicting metabolic associated fatty liver disease in obese children Yavuz Özer, Ersin Ulu, Emine Yurdakul Ertürk Pediatrics International.2025;[Epub] CrossRef
Serum complement C3 as a diagnostic biomarker for metabolic dysfunction -associated steatotic liver disease in middle-aged and elderly adults: a cross-sectional study Dan Ye, Haifen Ma, Jingjing Zhou, Jiaofeng Wang, Jiaheng Shi, Jie Chen, Zhijun Bao, Xiaona Hu BMC Gastroenterology.2025;[Epub] CrossRef
Attention-based graph neural network framework for non-invasive CAP score prediction in fatty liver disease via body modeling Ghasem Sadeghi Bajestani, Fatemeh Makhloughi, Ayoub Basham, Ebrahim Evazi, Mahdiyeh Razm Pour, Roohallah Alizadehsani, Farkhondeh Razmpour Physical and Engineering Sciences in Medicine.2025;[Epub] CrossRef
AI-Based Models for Risk Prediction in MASLD: A Systematic Review Basile Njei, Yazan A. Al-Ajlouni, Samira Yaya Lemos, Derek Ugwendum, Nelvis Njei, Omar Al Ta’ani, Prince Ameyaw, Lea-Pearl Njei, Sarpong Boateng Digestive Diseases and Sciences.2025;[Epub] CrossRef
Implementation of noninvasive liver disease screening tools in primary care Klaudia Nowak, Adrian Nowak, Aleksandra Jabłońska, Anna Potaczek, Julia Salacha, Natalia Dardzińska, Jakub Janczura Korean Journal of Family Medicine.2025; 46(6): 381. CrossRef
Steatosis-Associated Fibrosis Estimator Score in Asian Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Kunhee Kim, Hye Won Lee, Jae Seung Lee, Mi Na Kim, Jun Yong Park Yonsei Medical Journal.2025;[Epub] CrossRef
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim JAMA Internal Medicine.2024; 184(4): 375. CrossRef
Validation of a screening panel for pediatric metabolic dysfunction–associated steatotic liver disease using metabolomics Helaina E. Huneault, Alasdair E. Gent, Catherine C. Cohen, Zhulin He, Zachery R. Jarrell, Rishikesan Kamaleswaran, Miriam B. Vos Hepatology Communications.2024;[Epub] CrossRef
Screening the General Population for Non-Alcoholic Fatty Liver Disease: Model Development and Validation Tanya Mohammadi, Babak Mohammadi Archives of Medical Research.2024; 55(3): 102987. CrossRef
The associations between fibrosis changes and liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease Hye Won Lee, Kun Hee Kim, Sang Hoon Ahn, Han Chu Lee, Jonggi Choi Liver International.2024; 44(6): 1448. CrossRef
Evaluation of the ability of insulin resistance and lipid-related indices to predict the presence of NAFLD in obese adolescents Aylin Yetim, Memduh Şahin, İbrahim Kandemir, Betül Bulakçı, Melike Tuğrul Aksakal, Edanur Karapınar, Hayrettin Sever, Firdevs Baş Lipids in Health and Disease.2024;[Epub] CrossRef
Reference Range of Quantitative MRI Metrics Corrected T1 and Liver Fat Content in Children and Young Adults: Pooled Participant Analysis Elizabeth Shumbayawonda, Cayden Beyer, Benito de Celis Alonso, Silvia Hidalgo-Tobon, Briceida López-Martínez, Miguel Klunder-Klunder, América Liliana Miranda-Lora, E. Louise Thomas, Jimmy D. Bell, David J. Breen, Kamil Janowski, Maciej Pronicki, Wieslawa Children.2024; 11(10): 1230. CrossRef
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef
Non-Alcoholic Fatty Liver Disease, Awareness of a Diagnostic Challenge—A Clinician’s Perspective Cristina Maria Marginean, Denisa Pirscoveanu, Sergiu Marian Cazacu, Marian Sorin Popescu, Iulia Cristina Marginean, George Alexandru Iacob, Mihaela Popescu Gastroenterology Insights.2024; 15(4): 1028. CrossRef
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed Philipp Kasper, Münevver Demir, Hans-Michael Steffen Clinical and Molecular Hepatology.2023; 29(2): 390. CrossRef
Regression of nonalcoholic fatty liver disease is associated with reduced risk of incident diabetes: A longitudinal cohort study Dong Hyun Sinn, Danbee Kang, Eliseo Guallar, Sung Chul Choi, Yun Soo Hong, Yewan Park, Juhee Cho, Geum-Youn Gwak, Ahmed Mustafa Rashid PLOS ONE.2023; 18(7): e0288820. CrossRef
Non-alcoholic fatty liver disease – a challenging health problem of the 21st century Anamaria Cozma-Petruţ, Lorena Filip , Doina Miere Dietetician.ro.2023; 2(2): 30. CrossRef
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca Diagnostics.2023; 13(21): 3316. CrossRef
Waiting for the changes after the adoption of steatotic liver disease Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef
Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease Niketa Sharma, Swarupa Chakole, Bhushan Wandile Cureus.2023;[Epub] CrossRef
Alcohol consumption and the risk of liver disease: a nationwide, population-based study Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek Frontiers in Medicine.2023;[Epub] CrossRef
Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care Masato Yoneda, Takashi Kobayashi, Michihiro Iwaki, Asako Nogami, Satoru Saito, Atsushi Nakajima Gut and Liver.2023; 17(6): 843. CrossRef
MASLD and aspartame: are new studies in the horizon? Consolato M. Sergi Frontiers in Medicine.2023;[Epub] CrossRef
Sessiz Epidemi: Metabolik Disfonksiyon İlişkili Karaciğer Yağlanması Hastalığının Önlenmesine ve Yönetilmesine Yönelik Güncel Yaklaşımlar Ferya ÇELİK, Merve YÜKSEL, Hicran BEKTAŞ Artuklu International Journal of Health Sciences.2023; 3(3): 343. CrossRef
Background/Aims We investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of serum hepatitis B surface antigen (HBsAg).
Methods Serum viral biomarkers were measured at baseline, weeks 4, 12, 24, 36, and 48 of treatment. Patients were followed up thereafter and serum HBsAg level was measured at end of follow-up (EOFU). Favourable HBsAg response (FHR) was defined as ≤100 IU/mL or HBsAg seroclearance upon EOFU.
Results Twenty-eight hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients (median, 38.2 years old; 71.9% male) were recruited with median follow-up duration of 17.1 years (interquartile range, 12.8–18.2). For the entire cohort, 22/64 (34.4%) achieved FHR. For HBeAg-positive patients, serum HBV pgRNA decline at week 4 was significantly greater for patients with FHR compared to non-FHR (5.49 vs. 4.32 log copies/mL, respectively; P=0.016). The area under the receiver-operating-characteristic curve (AUROC) for week 4 HBV pgRNA reduction to predict FHR in HBeAg-positive patients was 0.825 (95% confidence interval [CI], 0.661–0.989). For HBeAg-negative patients, instead of increase in serum HBcrAg in non-FHR patients, FHR patients had median reduction in HBcrAg at week 4 (increment of 1.75 vs. reduction of 2.98 log U/mL; P=0.023). The AUROC for week 4 change of HBcrAg to predict FHR in HBeAg-negative patients was 0.789 (95% CI, 0.596–0.982).
Conclusions Early on-treatment changes of serum HBV pgRNA and HBcrAg at 4 weeks predict HBsAg seroclearance or ≤100 IU/mL in NA-treated CHB patients upon long-term FU.
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs Takanori Suzuki, Kentaro Matsuura, Takako Inoue, Hayato Kawamura, Kei Fujiwara, Hiromi Kataoka, Yasuhito Tanaka Hepatology Research.2025; 55(3): 309. CrossRef
Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure Yue Qiu, Qiao Tang, Xiao-Qing Liu, Yun-Ling Xue, Yi Zeng, Peng Hu World Journal of Hepatology.2025;[Epub] CrossRef
Serum O-glycosylated HBsAg levels correlate with HBV RNA in HBeAg positive CHB patients during antiviral therapy Bilian Yao, Qi Xu, Yousuke Yamada, Kiyohiko Angata, Yan Zhang, Hisashi Narimatsu, Demin Yu, Xinxin Zhang Antiviral Research.2025; 234: 106077. CrossRef
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters Lung-Yi Mak, Mark Anderson, Michael Stec, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, Rex Wan-Hin Hui, Wai-Kay Seto, Gavin Cloherty, Man-Fung Yuen Clinical and Molecular Hepatology.2025; 31(2): 460. CrossRef
HBcrAg Dynamic Change During Treatment Predicts HBsAg Loss in Pediatric Patients With Chronic Hepatitis B Ling Ye, Wenxian Ouyang, Yingping Gu, Zhenzhen Yao, Xin Lai, Sisi Li, Meng Yang, Songxu Peng Journal of Medical Virology.2025;[Epub] CrossRef
Dynamics of HBV biomarkers during nucleos(t)ide analog treatment: A 14-year study Florian van Bömmel, Elisabetta Degasperi, Alena van Bömmel, Floriana Facchetti, Dana Sambarino, Danilo Deichsel, Jessica Brehm, Rodrigue Kamga Wouambo, Melanie Maier, Maria Pfefferkorn, Thomas Berg, Pietro Lampertico Hepatology Communications.2025;[Epub] CrossRef
Profiles of HBV DNA integration in humans with hepatitis B virus infection: Insights for antiviral treatment Rex Wan-Hin Hui, Danny Ka-Ho Wong, Xueying Lyu, Lung-Yi Mak, James Fung, Wai-Kay Seto, Daniel Wai-Hung Ho, Man-Fung Yuen JHEP Reports.2025; 7(9): 101487. CrossRef
Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine Yaru Shi, Rong Fan Interdisciplinary Medicine.2025;[Epub] CrossRef
Clinical value of serum HBV RNA in patients with chronic hepatitis B during antiviral therapy Xiaojing Zhang, Fengmin Lu, Rui Wu, Qiaofei Jin, Yijun Zhou, Chen Wang, Huaguo Shao, Shourong Liu PeerJ.2025; 13: e20275. CrossRef
Changes in Hepatitis B Core Antigen and Hepatitis B Surface Antigen Expression Following Antiviral Therapy and Their Role in Outcome of Patients With Chronic Hepatitis B Mohammed Rifat Shaik, Lauren Apodaca, Sungyoung Auh, Meera Kattapuram, Gavin A. Cloherty, David E. Kleiner, Marc G. Ghany Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Hepatitis B virus functional cure in persons with HIV: what are the predictors and which novel markers are useful? Lorin Begré, Fabien Zoulim, Anders Boyd Current Opinion in HIV and AIDS.2025;[Epub] CrossRef
Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy Liandong Wu, Zhenggang Yang, Min Zheng Journal of Viral Hepatitis.2024; 31(5): 255. CrossRef
Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation” Yun-Fan Liaw Clinical and Molecular Hepatology.2024; 30(2): 269. CrossRef
Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy Lorin Begré, Anders Boyd, Marie-Laure Plissonnier, Barbara Testoni, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Caroline Scholtès, Charles Béguelin, Jürgen K Rockstroh, Huldrych F Günthard, Alexandra Calmy, Matthias Cavassini, Hans H Hirsch, Patrick S The Journal of Infectious Diseases.2024;[Epub] CrossRef
Detection technology and clinical applications of serum viral products of hepatitis B virus infection Ying Liu, Di Wu, Kui Zhang, Rongrong Ren, Yuxuan Liu, Shuya Zhang, Xuanyu Zhang, Jilin Cheng, Liping Chen, Jun Huang Frontiers in Cellular and Infection Microbiology.2024;[Epub] CrossRef
Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB” Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 191. CrossRef
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block? Young-Suk Lim Clinical and Molecular Hepatology.2023; 29(1): 118. CrossRef
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2023; 29(1): 113. CrossRef
Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers Lung-Yi Mak, Rex Wan-Hin Hui, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen Expert Opinion on Drug Discovery.2023; 18(4): 401. CrossRef
Utility of novel viral and immune markers in predicting HBV treatment endpoints: A systematic review of treatment discontinuation studies Georgia Zeng, Apostolos Koffas, Lung-Yi Mak, Upkar S. Gill, Patrick T.F. Kennedy JHEP Reports.2023; 5(6): 100720. CrossRef
The role of different viral biomarkers on the management of chronic hepatitis B Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2023; 29(2): 263. CrossRef
Past, present, and future of long-term treatment for hepatitis B virus Teresa Broquetas, José A Carrión World Journal of Gastroenterology.2023; 29(25): 3964. CrossRef
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved clinical outcomes. However, functional cure is rarely attainable by current treatment modalities. RNA interference (RNAi) by small-interfering RNA (siRNA) and anti-sense oligonucleotide (ASO) has been studied as a novel treatment strategy for CHB. RNAi targets post-transcriptional messenger RNAs and pregenomic RNAs to reduce hepatitis B virus (HBV) antigen production and viral replication. By reducing viral antigens, host immune reconstitution against HBV may also be attained. Phase I/II trials on siRNAs have demonstrated them to be safe and well-tolerated. siRNA is effective when given in monthly doses with different total number of doses according to different trial design, and can lead to sustainable dose-dependent mean HBsAg reduction by 2–2.5 log. Incidences of HBsAg seroclearance after siRNA therapy have also been reported. ASOs have also been studied in early phase trials, and a phase Ib study using frequent dosing regimen within 4 weeks could achieve similar HBsAg reduction of 2 log from baseline. Given the established efficacy and safety of nucleos(t) ide analogues (NAs), future RNAi regimens will likely include NA backbone. While the current evidence on RNAi appears promising, it remains undetermined whether the potent HBsAg reduction by RNAi can result in a high rate of HBsAg seroclearance with durability. Data on RNAi from phase IIb/III trials are keenly anticipated.
Citations
Citations to this article as recorded by
Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure Rex Wan-Hin Hui, Trevor Kwan-Hung Wu, Karen Cheuk-Ying Ho, Ryan Hin-Man Leung, Matthew Shing-Hin Chung, Danny Ka-Ho Wong, James Fung, Wai-Kay Seto, Lung Yi Mak, Man-Fung Yuen Gut.2026; 75(1): 119. CrossRef
Update on combination therapies against HBV in clinical investigations Lung-Yi Mak, Anna SF. Lok Antiviral Research.2026; 245: 106321. CrossRef
Targeting the innate immune system in treating hepatitis B: prospects for functional cure Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Clinical and Molecular Hepatology.2026; 32(1): 184. CrossRef
RNA nanomedicine in liver diseases Anita Bakrania, Yulin Mo, Gang Zheng, Mamatha Bhat Hepatology.2025; 81(6): 1847. CrossRef
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989 Lung Yi Mak, Christine I Wooddell, Oliver Lenz, Thomas Schluep, James Hamilton, Heather L Davis, Xianhua Mao, Wai-Kay Seto, Michael Biermer, Man-Fung Yuen Gut.2025; 74(3): 440. CrossRef
Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA Jihua Ren, Shengtao Cheng, Fang Ren, Huiying Gu, Daiqing Wu, Xinyan Yao, Ming Tan, Ailong Huang, Juan Chen Genes & Diseases.2025; 12(1): 101215. CrossRef
Investigational RNA Interference Agents for Hepatitis B Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen BioDrugs.2025; 39(1): 21. CrossRef
Reply to: “ALT to qHBsAg ratio predicts HBsAg seroclearance in HBeAg-negative patients receiving Peg-IFNα based therapy” Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen Journal of Hepatology.2025; 82(5): e228. CrossRef
Inhibition of Hepatitis B Virus Replication by a Novel GalNAc–siRNA In Vivo and In Vitro Zhipeng Zhang, Yanqin Ma, Yan He, Dong Wang, Kun Yue, Xiaomei Zhang, Huaien Song ACS Omega.2025; 10(1): 484. CrossRef
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases Zhen-Xin Qin, Ling Zuo, Ziran Zeng, Rongguan Ma, Wenyan Xie, Xiao Zhu, Xiaorong Zhou Expert Opinion on Drug Delivery.2025; 22(4): 455. CrossRef
Expanding treatment indications in chronic hepatitis B: Should we treat all patients? Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Hepatology International.2025; 19(2): 304. CrossRef
Prospect of emerging treatments for hepatitis B virus functional cure Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen Clinical and Molecular Hepatology.2025; 31(Suppl): S165. CrossRef
Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0 Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Clinical and Molecular Hepatology.2025; 31(Suppl): S134. CrossRef
CTLA4 modulates B cell receptor signals to inhibit HBsAb secretion in chronic hepatitis B patients Shengxia Yin, Minxin Mao, Linyan Gong, Yijia Zhu, Yawen Wan, Xin Tong, Jian Wang, Guiyang Wang, Yong Liu, Chao Wu, Rui Huang, Yuxin Chen Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(6): 167848. CrossRef
Racing toward the future of chronic hepatitis B management: Achieving functional cure and enhancing hepatocellular carcinoma surveillance through precision medicine Yaru Shi, Rong Fan Interdisciplinary Medicine.2025;[Epub] CrossRef
Advances in the management of hepatitis B Ruma Rajbhandari, Vy H Nguyen, Abigail Knoble, Gregory Fricker, Raymond T Chung BMJ.2025; 389: e079579. CrossRef
Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak Hepatology International.2025; 19(4): 704. CrossRef
Targeting HBV with RNA interference: Paths to cure Matteo Iannacone, Cristian G. Beccaria, Lena Allweiss, Julie Lucifora, John E. Tavis, Adam J. Gehring, Maura Dandri Science Translational Medicine.2025;[Epub] CrossRef
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure Ana Verma, Raymond T. Chung Current Opinion in HIV and AIDS.2025; 20(5): 449. CrossRef
Virological Insights from ARC-520 siRNA and Entecavir Treated Chronically HBV-Infected Patients and Chimpanzees Christine I. Wooddell, Lung Yi Mak, Wai-Kay Seto, Bruce D. Given, Man-Fung Yuen Microorganisms.2025; 13(8): 1787. CrossRef
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D Junjie Liu, Tong Yuan, Lin Xue, Huifang Liang Virology Journal.2025;[Epub] CrossRef
Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B Lu Zhang, Yu Cao, Sijing Zhuang, Jingjing Sun, Qiao Tong, Jianjun Xi, Shourong Liu, Rangxiao Zhuang Frontiers in Pharmacology.2025;[Epub] CrossRef
Functional cure for chronic hepatitis B: A state of immune control over cccDNA persistence Kunyu Zhao, Lili Wu, Yu Wu, Qianqian Jiang, Mengmeng Zhu, Suzhen Jiang, Chao Zhang, Fengmin Lu Infectious Diseases & Immunity.2025;[Epub] CrossRef
Hepatitis B functional cure: Current and future perspective Sudheer Marrapu, Jinit R Soni, Kislaya Kamal, Ramesh Kumar World Journal of Hepatology.2025;[Epub] CrossRef
Strategies to Achieve Functional Cure in HBV: Focus on siRNA Eyyel Karthikeyan, Robert G. Gish Current Hepatology Reports.2025;[Epub] CrossRef
Individualizing endpoints in chronic HBV treatment: HBsAg loss and beyond Milan J. Sonneveld, Harry L.A. Janssen Journal of Hepatology.2025;[Epub] CrossRef
In-Silico Development of Effective Short Hairpin RNA Molecules Targeting the Transactivator Region of Human Hepatitis B Virus Amir Pouremamali, Mehrdad Ravanshad, Leila Asadi Samani, Farhad Pouremamali, Reza Ghanbari Jundishapur Journal of Microbiology.2025;[Epub] CrossRef
Functional cure of chronic hepatitis B virus infection: current therapeutic regimens Yi-Wei Shi, Rui Pu, Yi-Bo Ding, Wen-Bin Liu, Zi-Shuai Li, Jia-Yi Zhao, Yi-Fan Chen, Guang-Wen Cao Hepatoma Research.2025;[Epub] CrossRef
Recent Progress in Phage‐Based Nanoplatforms for Tumor Therapy Xiao‐Tong Li, Shu‐Yi Peng, Shao‐Mei Feng, Ting‐Yu Bao, Sheng‐Zhang Li, Shi‐Ying Li Small.2024;[Epub] CrossRef
Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics Jie-Li Hu, Ai-Long Huang Virologica Sinica.2024; 39(1): 9. CrossRef
Cytosine base editing inhibits hepatitis B virus replication and reduces HBsAg expression in vitro and in vivo Elena M. Smekalova, Maria G. Martinez, Emmanuel Combe, Anuj Kumar, Selam Dejene, Dominique Leboeuf, Chao-Ying Chen, J. Robert Dorkin, Lan Shuan Shuang, Sarah Kieft, Lauren Young, Luis Alberto Barrera, Michael S. Packer, Giuseppe Ciaramella, Barbara Teston Molecular Therapy Nucleic Acids.2024; 35(1): 102112. CrossRef
Can Radionuclide Therapy be the Solution for Hepatitis B Virus Infection? Pil Soo Sung, Ie Ryung Yoo Nuclear Medicine and Molecular Imaging.2024; 58(5): 255. CrossRef
Preclinical Antiviral and Safety Profiling of the HBV RNA Destabilizer AB-161 Angela M. Lam, Ravi R. Dugyala, Muhammed Sheraz, Fei Liu, Emily P. Thi, Ingrid E. Graves, Andrea Cuconati, Holly Micolochick Steuer, Andrzej Ardzinski, Nathan Overholt, Jeremy D. Mason, Dimitar Gotchev, Andrew G. Cole, Troy O. Harasym, Michael J. Sofia Viruses.2024; 16(3): 323. CrossRef
Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model Ellen Van Gulck, Nádia Conceição-Neto, Liese Aerts, Wim Pierson, Lore Verschueren, Mara Vleeschouwer, Vinod Krishna, Isabel Nájera, Frederik Pauwels Viruses.2024; 16(3): 347. CrossRef
Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang World Journal of Gastroenterology.2024; 30(10): 1295. CrossRef
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873 Darryl Kato, Regina Wai-Yan Choy, Eda Canales, Ryan A. Dick, April D. Lake, Nathan D. Shapiro, Elbert Chin, Jiayao Li, Jennifer R. Zhang, Qiaoyin Wu, Roland D. Saito, Sammy Metobo, Evangelos Aktoudianakis, Scott D. Schroeder, Zheng-Yu Yang, Dylan M. Glatt ACS Medicinal Chemistry Letters.2024; 15(4): 546. CrossRef
Model‐based meta‐analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B‐infected mice Louis Sandra, Huybrecht T'jollyn, An Vermeulen, Oliver Ackaert, Juan‐Jose Perez‐Ruixo CPT: Pharmacometrics & Systems Pharmacology.2024; 13(5): 729. CrossRef
Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: A comprehensive review of phases II and III therapeutic agents Robert Lam, Joseph K Lim World Journal of Hepatology.2024; 16(3): 331. CrossRef
Prospects for Controlling Hepatitis B Globally Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza Pathogens.2024; 13(4): 291. CrossRef
Therapeutic advances in HBV cure Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen Clinical Liver Disease.2024;[Epub] CrossRef
Genotyping Hepatitis B virus by Next-Generation Sequencing: Detection of Mixed Infections and Analysis of Sequence Conservation Eva Dopico, Marta Vila, David Tabernero, Josep Gregori, Ariadna Rando-Segura, Beatriz Pacín-Ruíz, Laura Guerrero, Itziar Ubillos, Miguel J. Martínez, Josep Costa, Josep Quer, Javier Pérez-Garreta, Alejandra González-Sánchez, Andrés Antón, Tomás Pumarola, International Journal of Molecular Sciences.2024; 25(10): 5481. CrossRef
Analysis of the pharmacokinetics and efficacy of RBD1016 – A GalNAc-siRNA targeting Hepatitis B Virus X gene using semi-mechanistic PK/PD model Qian Li, Taohua Geng, Haiyan Li, Shuquan Zheng, Sara Svedlund, Liming Gan, Ann-Charlotte Egnell, Shan Gao, Rui Chen, Pei Hu Heliyon.2024; 10(11): e31924. CrossRef
Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection Wenjing Zai, Min Yang, Kuan Jiang, Juan Guan, Huijing Wang, Kongying Hu, Chao Huang, Jieliang Chen, Wei Fu, Changyou Zhan, Zhenghong Yuan Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Discovery of hepatitis B virus subviral particle biogenesis inhibitors from a bioactive compound library Biplav Shrestha, Sisi Yang, Lauren Griffith, Julia Ma, Fuxuan Wang, Hui Liu, Qiong Zhao, Yanming Du, Jiming Zhang, Jinhong Chang, Ju-Tao Guo Antiviral Research.2024; 228: 105955. CrossRef
Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim Clinical and Molecular Hepatology.2024; 30(3): 539. CrossRef
Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain Lanlan Liu, Haoyu Wang, Lulu Liu, Fang Cheng, Haji Akber Aisa, Changfei Li, Songdong Meng Viruses.2024; 16(7): 1151. CrossRef
The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy Mingming Zhang, Han Chen, Huan Liu, Hong Tang Biomarker Research.2024;[Epub] CrossRef
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study Man-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, Tien-Huey Lim, Jeong Heo, Pisit Tangkijvanich, Won Young Tak, Vaidehi Thanawala, Daniel Cloutier, Shenghua Mao, Andre Arizpe, Andrea L Cathcart, Sneha V Gupta, Carey Hwang, Edward Gane The Lancet Gastroenterology & Hepatology.2024; 9(12): 1121. CrossRef
Novel NTCP ligand dimeric bile acid conjugated with ASO reduce hepatitis B virus surface antigen in vivo Lei Lu, Dezi Cong, Tinghong Lv, Haisheng Wang, Xiaolei Wang European Journal of Medicinal Chemistry.2024; 280: 116955. CrossRef
Chitosan/siRNA nanoparticles targeting PARP-1 attenuate Neuroinflammation and apoptosis in hyperglycemia-induced oxidative stress in Neuro2a cells Moqbel Ali Moqbel Redhwan, Hariprasad M.G., Suman Samaddar, Duaa Abdullah Bafail, Sumaia Abdulbari Ahmed Ali Hard, Sourav Guha International Journal of Biological Macromolecules.2024; 282: 136964. CrossRef
A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses Mohadeseh Hasanpourghadi, Mikhail Novikov, Robert Ambrose, Arezki Chekaoui, Dakota Newman, ZhiQuan Xiang, Andrew D. Luber, Sue L. Currie, XiangYang Zhou, Hildegund C.J. Ertl JCI Insight.2024;[Epub] CrossRef
Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates Linh Nguyen, Tiep Tien Nguyen, Ju-Yeon Kim, Jee-Heon Jeong Journal of Nanobiotechnology.2024;[Epub] CrossRef
Utilizing Engineered Bacteria as “Cell Factories” In Vivo for Intracellular RNA-Loaded Outer Membrane Vesicles’ Self-Assembly in Tumor Treatment Dawei Sun, Yize Li, Xiaoxuan Yin, Yali Fan, Jing Liu, Yaxin Wang, Xinyu Liu, Guijie Bai, Ke Li, Yanyan Shi, Peiyuan Liu, Yingying Zhang, Hanjie Wang ACS Nano.2024; 18(52): 35296. CrossRef
Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ‐73763989 in Healthy Chinese Adult Participants Haiyan Li, Xiaoye Niu, Yu Zhang, Danning Zhang, Yanqing Zhang, Liqun Wang, Yongqing Miao, Yanxin Jiang, Jia Ji, Qiaoqiao Chen, Xiaoyun Wu, Emmanuel Njumbe Ediage, Thomas N. Kakuda, Michael Biermer Clinical Pharmacology in Drug Development.2023; 12(2): 175. CrossRef
Therapies against chronic hepatitis B infections: The times they are a-changin’, but the changing is slow! David Durantel Antiviral Research.2023; 210: 105515. CrossRef
New Approaches to Chronic Hepatitis B Dan L. Longo, Geoffrey Dusheiko, Kosh Agarwal, Mala K. Maini New England Journal of Medicine.2023; 388(1): 55. CrossRef
The scientific basis of combination therapy for chronic hepatitis B functional cure Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 238. CrossRef
Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review Jie-Li Hu, Ai-Long Huang Microorganisms.2023; 11(3): 600. CrossRef
Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui The Lancet Regional Health - Western Pacific.2023; 35: 100738. CrossRef
The progress of molecules and strategies for the treatment of HBV infection Youlu Pan, Heye Xia, Yanwen He, Shenxin Zeng, Zhengrong Shen, Wenhai Huang Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen, James Fung Expert Review of Gastroenterology & Hepatology.2023; 17(5): 443. CrossRef
Current and novel modalities for management of chronic hepatitis B infection Iman Ibrahim Salama, Samia M Sami, Somaia I Salama, Ghada A Abdel-Latif, Fatma A Shaaban, Walaa A Fouad, Aida M Abdelmohsen, Hala M Raslan World Journal of Hepatology.2023; 15(5): 585. CrossRef
Past, present, and future of long-term treatment for hepatitis B virus Teresa Broquetas, José A Carrión World Journal of Gastroenterology.2023; 29(25): 3964. CrossRef
Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers Lung-Yi Mak, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen Clinics in Liver Disease.2023; 27(4): 877. CrossRef
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease Pavel Strnad, Javier San Martin Expert Opinion on Investigational Drugs.2023; 32(7): 571. CrossRef
Chronic Hepatitis B Infection: New Approaches towards Cure Mojisola Ogunnaike, Srijanee Das, Samiksha S. Raut, Ashrafi Sultana, Mohammad Ullah Nayan, Murali Ganesan, Benson J. Edagwa, Natalia A. Osna, Larisa Y. Poluektova Biomolecules.2023; 13(8): 1208. CrossRef
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai-Kay Seto, Man-Fung Yuen Expert Opinion on Investigational Drugs.2023; 32(11): 971. CrossRef
Cell-Penetrating Peptides as Vehicles for Delivery of Therapeutic Nucleic Acids. Mechanisms and Application in Medicine Ekaterina D. Timotievich, Igor P. Shilovskiy, Musa R. Khaitov Biochemistry (Moscow).2023; 88(11): 1800. CrossRef
Gene-Editing and RNA Interference in Treating Hepatitis B: A Review Nadiia Kasianchuk, Krystyna Dobrowolska, Sofiia Harkava, Andreea Bretcan, Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, Robert Flisiak, Piotr Rzymski Viruses.2023; 15(12): 2395. CrossRef
Peptide carriers as delivery vehicles for therapeutic nucleic acids. Мechanisms and potential applications in medicine E. D Timotievich, I. P Shilovskiy, M. R Khaitov Биохимия.2023; 88(11): 2183. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials Rex Wan-Hin Hui, Lung Yi Mak, Wai-Kay Seto, Man-Fung Yuen Expert Opinion on Emerging Drugs.2022; 27(2): 127. CrossRef
Antigen Load and T Cell Function: A Challenging Interaction in HBV Infection Ilaria Montali, Andrea Vecchi, Marzia Rossi, Camilla Tiezzi, Amalia Penna, Valentina Reverberi, Diletta Laccabue, Gabriele Missale, Carolina Boni, Paola Fisicaro Biomedicines.2022; 10(6): 1224. CrossRef
Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B Mark A. Feitelson, Alla Arzumanyan, Ira Spector, Arvin Medhat Biomedicines.2022; 10(9): 2210. CrossRef
Novel Combination Strategies With Investigational Agents for Functional Cure of Chronic Hepatitis B Infection Rex Wan-Hin Hui, Lung-Yi Mak, Ka-Shing Cheung, James Fung, Wai-Kay Seto, Man-Fung Yuen Current Hepatology Reports.2022; 21(4): 59. CrossRef
State-of-the-art and emerging antivirals for chronic hepatitis B infection Margarita Papatheodoridi, George V. Papatheodoridis Expert Opinion on Pharmacotherapy.2022; 23(18): 1999. CrossRef
First
Prev
